The co-administration of intranasal insulin and GLP-1RA as targeting drugs for prophylaxis and treatment of post COVID-19 smell and taste dysfunctions and brain fog

Abstract

ABSTRACT The coronavirus disease (COVID-19) pandemic has resulted in high infection rates, significant morbidity, and postmortality among older adults, resulting in a global burden of COVID-19 survivors’ long-term care. Post-COVID-19 syndrome appears to affect a significant proportion of people who have recovered from acute COVID-19. Fatigue, brain fog, and a lack of smell and/or taste are all common and debilitating symptoms of the post-COVID-19 syndrome. Even though many people suffer from smell dysfunction as a symptom of post-COVID-19 syndrome, there has been no definite treatment until now. We bring forward this novel idea to encourage scientists to conduct clinical research to improve the quality of life of most people affected by these symptoms. In addition, some clinical trials have been conducted already by the Ministry of Minea University, Egypt.